Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 주식 보고서

시가총액: HK$972.0m

Charmacy Pharmaceutical 과거 수익 실적

과거 기준 확인 2/6

Charmacy Pharmaceutical has been growing earnings at an average annual rate of 16.1%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 4.9% per year. Charmacy Pharmaceutical's return on equity is 8.7%, and it has net margins of 1.2%.

주요 정보

16.1%

수익 성장률

16.1%

EPS 성장률

Healthcare 산업 성장11.3%
매출 성장률4.9%
자기자본 수익률8.7%
순이익1.2%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

수익 및 비용 분석

Charmacy Pharmaceutical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SEHK:2289 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 244,482521760
31 Mar 244,443521730
31 Dec 234,404511710
30 Sep 234,480741730
30 Jun 234,557961750
31 Mar 234,366931700
31 Dec 224,175901650
30 Sep 223,931541590
30 Jun 223,688181530
31 Mar 223,741201520
31 Dec 213,794231520
30 Sep 213,959291530
30 Jun 214,124361540
31 Mar 214,058381490
31 Dec 203,992411430
30 Sep 203,819351370
30 Jun 203,645291300
31 Mar 203,569341290
31 Dec 193,493401280
30 Sep 193,557411270
30 Jun 193,621421250
31 Mar 193,778441280
31 Dec 183,935451300
30 Sep 184,075461290
30 Jun 184,214471280
31 Mar 184,155461240
31 Dec 174,096451200
30 Sep 173,946541120
30 Jun 173,796631040
31 Mar 173,73360980
31 Dec 163,67056930
30 Sep 163,60547880
30 Jun 163,54038830
31 Mar 163,46832820
31 Dec 153,39726810
30 Sep 153,29931820
30 Jun 153,20035830
31 Mar 153,10736780
31 Dec 143,01436730
31 Dec 132,40122590

양질의 수익: 2289 has high quality earnings.

이익 마진 증가: 2289's current net profit margins (1.2%) are lower than last year (2.1%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 2289's earnings have grown by 16.1% per year over the past 5 years.

성장 가속화: 2289's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

수익 대 산업: 2289 had negative earnings growth (-46.2%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).


자기자본 수익률

높은 ROE: 2289's Return on Equity (8.7%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기